My Bibliography

select

Mack E, Dougher M, Ginda A, Cahill C, Murter M, Schell K, Tanhehco Y, Bhoj V, Fesnak A, Siegel D, Kambayashi T, Aqui N, O'Doherty U. Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis. Blood Journal. 2023 December; :-. doi: 10.1182/blood.2023021895.

select

Wang K, Tseng C, Li Z, White C, Wang B, Levine B, Fesnak A. A simulation-based comparison of centralized and point-of-care supply chain strategies for autologous cell therapy. Cytotherapy. 2023 December; 25(12):1370-1379. doi: 10.1016/j.jcyt.2023.08.007.

select

Fesnak A, Siegel D. Chimeric antigen receptor T cells and other cellular immunotherapies. In: Simon T, Gehrie E, McCullough J, Roback J, Snyder E, editors. Rossi's Principles of Transfusion Medicine [Internet] 1 ed. Wiley; 2022-08. 633-641p. Available from: https://onlinelibrary.wiley.com/doi/10.1002/9781119719809.ch55.

select

Guleria I, de Los Angeles Muñiz M, Wilgo M, Bapat A, Cui W, Hsu Y, Jeyaraman M, Muthu S, Rodriguez F, Fesnak A, Celluzzi C, Sesok‐Pizzini D, Reich‐Slotky R, Spitzer T. How do I: Evaluate the safety and legitimacy of unproven cellular therapies?. Transfusion. 2022 February; 62(3):518-532. doi: 10.1111/trf.16814.

select

Bar KJ, Shaw PA, Choi GH, Aqui N, Fesnak A, Yang JB, Soto-Calderon H, Grajales L, Starr J, Andronov M, Mastellone M, Amonu C, Feret G, DeMarshall M, Buchanan M, Caturla M, Gordon J, Wanicur A, Monroy MA, Mampe F, Lindemuth E, Gouma S, Mullin AM, Barilla H, Pronina A, Irwin L, Thomas R, Eichinger RA, Demuth F, Luning Prak ET, Pascual JL, Short WR, Elovitz MA, Baron J, Meyer NJ, Degnan KO, Frank I, Hensley SE, Siegel DL, Tebas P. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest. 2021 Dec 15;131(24). doi: 10.1172/JCI155114. PubMed PMID: 34788233; PubMed Central PMCID: PMC8670841.

select

Bar K, Shaw P, Choi G, Aqui N, Fesnak A, Yang J, Soto-Calderon H, Grajales L, Starr J, Andronov M, Mastellone M, Amonu C, Feret G, DeMarshall M, Buchanan M, Caturla M, Gordon J, Wanicur A, Monroy M, Mampe F, Lindemuth E, Gouma S, Mullin A, Barilla H, Pronina A, Irwin L, Thomas R, Eichinger R, Demuth F, Luning Prak E, Pascual J, Short W, Elovitz M, Baron J, Meyer N, Degnan K, Frank I, Hensley S, Siegel D, Tebas P. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation. 2021 December; 131(24):-. doi: 10.1172/JCI155114.

select

Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, Aplenc R, Baniewicz D, Liu H, Shaw PA, Pequignot E, Getz KD, Brogdon JL, Fesnak AD, Siegel DL, Davis MM, Bartoszek C, Lacey SF, Hexner EO, Chew A, Wertheim GB, Levine BL, June CH, Grupp SA, Maude SL. Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2021 Sep 20;39(27):3044-3055. doi: 10.1200/JCO.20.03458. Epub 2021 Jun 22. PubMed PMID: 34156874; PubMed Central PMCID: PMC9851702.

select

Abou-el-Enein M, Elsallab M, Feldman S, Fesnak A, Heslop H, Marks P, Till B, Bauer G, Savoldo B. Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy. Blood Cancer Discovery. 2021 September; 2(5):408-422. doi: 10.1158/2643-3230.BCD-21-0084.

select

Golden RJ, Fesnak AD. Clinical development of natural killer cells expressing chimeric antigen receptors. Transfus Apher Sci. 2021 Feb;60(1):103065. doi: 10.1016/j.transci.2021.103065. Epub 2021 Jan 10. Review. PubMed PMID: 33468407; PubMed Central PMCID: PMC10029926.

select

Lamontagne A, Fesnak A. Limiting variability to achieve reproducibility in cell manufacturing. Cell and Gene Therapy Insights. 2020 November; 6(10):157-1363. doi: 10.18609/cgti.2020.149.

select

Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020 Feb 28;367(6481). doi: 10.1126/science.aba7365. Epub 2020 Feb 6. PubMed PMID: 32029687; NIHMSID:NIHMS1859857.

select

Bersenev A, Fesnak A. Place of Academic GMP Facilities in Modern Cell Therapy. Methods Mol Biol. 2020;2097:329-339. doi: 10.1007/978-1-0716-0203-4_21. PubMed PMID: 31776936.

select

Stadtmauer E, Cohen A, Weber K, Lacey S, Gonzalez V, Melenhorst J, Fraietta J, Plesa G, Shea J, Matlawski T, Cervini A, Mangan P, Gaymon A, Desjardins S, Lancaster E, Salas-Mckee J, Suhoski M, Fesnak A, O'Rourke M, Lamontagne A, Siegel D, Young R, Chew A, Nobles C, Bushman F, Chang H, Satpathy A, Zhao Y, Hwang W, Hexner E, June C. First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. Blood. 2019 November; 134(Supplement_1):49-49. doi: 10.1182/blood-2019-122374.

select

Garfall A, Cohen A, Lacey S, Tian L, Hwang W, Vogl D, Waxman A, Lancaster E, Nelson A, Ferthio R, Fesnak A, Lamontagne A, Brennan A, Guilliams J, Gladney W, Melenhorst J, Young R, Siegel D, Levine B, Brogdon J, Isaacs R, June C, Milone M, Stadtmauer E. Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma. Blood. 2019 November; 134(Supplement_1):1863-1863. doi: 10.1182/blood-2019-131515.

select

Wang K, Liu Y, Li J, Wang B, Bishop R, White C, Das A, Levine AD, Ho L, Levine BL, Fesnak AD. A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies. Cytotherapy. 2019 Oct;21(10):1081-1093. doi: 10.1016/j.jcyt.2019.07.002. Epub 2019 Aug 21. PubMed PMID: 31445816.

select

Fesnak A. The Challenge of Variability in Chimeric Antigen Receptor T Cell Manufacturing. Regenerative Engineering and Translational Medicine. 2019 August; 6(3):322-329. doi: 10.1007/s40883-019-00124-3.

select

Ohayon Y, Corl C, Leskowitz R, Malykhin A, Arostegui S, Hennesy N, Ngo S, Levine B, Siegel D, Fesnak A, Davis M. Robust automated cell counter and viability measurement for engineered T cell product release. Cytotherapy. 2018 May; 20(5):S69-. doi: 10.1016/j.jcyt.2018.02.193.

select

Fesnak AD, Hanley PJ, Levine BL. Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy. Curr Hematol Malig Rep. 2017 Aug;12(4):335-343. doi: 10.1007/s11899-017-0395-9. Review. PubMed PMID: 28762038; PubMed Central PMCID: PMC5693739.

select

Davis MM, Fesnak AD, Leskowitz RM, Mckee JS, Ohayon Y, Corl CM, Malykhin A, Fraietta JA, Melenhorst JJ, June CH, Schuster S. Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL). Cytotherapy. 2017 May; 19(5):S118-9.

select

Levine B, Fesnak A, Riviere I. Showcasing Clinical Development and Production of Cellular Therapies. Molecular Therapy. 2017 April; 25(4):827-828. doi: 10.1016/j.ymthe.2017.03.007.

select

Fesnak A, O'Doherty U. Clinical Development and Manufacture of Chimeric Antigen Receptor T cells and the Role of Leukapheresis. European Oncology & Haematology. 2017; 13(1):28-34. doi: 10.17925/EOH.2017.13.01.28.

select

Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016 Aug 23;16(9):566-81. doi: 10.1038/nrc.2016.97. Review. PubMed PMID: 27550819; PubMed Central PMCID: PMC5543811.

select

Fesnak A, Lin C, Siegel DL, Maus MV. CAR-T Cell Therapies From the Transfusion Medicine Perspective. Transfus Med Rev. 2016 Jul;30(3):139-45. doi: 10.1016/j.tmrv.2016.03.001. Epub 2016 Mar 28. Review. PubMed PMID: 27067907; PubMed Central PMCID: PMC4914456.

select

Levine B, Maude S, Zheng Z, Shaw P, Ambrose D, Aplenc R, Barker C, Barrett D, Brogdon J, Callahan C, Chen F, Chew A, Suhoski Davis M, Fesnak A, Finklestein J, Frey N, Lacey S, Lamontagne A, Lewitt L, Loew A, Marcucci K, Melenhorst J, Motley L, Mudambi M, Nazimuddin F, O'Rourke M, Porter D, Rheingold S, Scholler J, Tayor C, White C, Wood P, Young R, Teachey D, June C, Grupp S. Durable Remissions with Control of Cytokine Release Syndrome (CRS) Using T Cells Expressing CD19 Targeted Chimeric Antigen Receptor (CAR) CTL019 to Treat Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL). Cytotherapy. 2016 June; 18(6):S14-S15. doi: 10.1016/j.jcyt.2016.03.039.

select

Karimi M, Bryson J, Richman L, Fesnak A, Leichner T, Satake A, Vonderheide R, Raulet D, Reshef R, Kambayashi T. NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT. Blood. 2015 June; 125(23):3655-3663. doi: 10.1182/blood-2015-02-629006.

select

Fesnak A. Conceptualizing Physician Professionalism. JAMA. 2011 April; 305(14):1411-. doi: 10.1001/jama.2011.425.

select

Vinocur JM, Fesnak AD, Liu Y, Charan D, Prak ET. Violations of the 12/23 rule at the mouse immunoglobulin kappa locus, including V kappa-V kappa rearrangement. Mol Immunol. 2009 Jul;46(11-12):2183-9. doi: 10.1016/j.molimm.2009.04.021. Epub 2009 May 20. PubMed PMID: 19467709; PubMed Central PMCID: PMC2697664.

select

Vinocur J, Fesnak A, Liu Y, Charan D, Luning Prak E. Violations of the 12/23 rule at the mouse immunoglobulin kappa locus, including Vκ-Vκ rearrangement. Molecular Immunology. 2009 July; 46(11-12):2183-2189. doi: 10.1016/j.molimm.2009.04.021.

select

Kotlyar, David, Perez, Elena, Blonski, Wojciech, Brensinger, Colleen, Fesnak, Andrew, Lin, Ming, Mendizabal, Manuel, Lichtenstein, Gary. A Meta-analysis of GI complications in Common Variable Immune Deficiency (CVID). American Journal of Gastroenterology. 2009; 104:S437.

select

Kotlyar, David, Perez, Elena, Blonski, Wojciech, Brensinger, Colleen, Fesnak, Andrew, Lin, Ming, Mendizabal, Manuel, Lichtenstein, Gary. A Meta-analysis of Hepatic Complications in Common Variable Immune Deficiency (CVID). American Journal of Gastroenterology. 2009; 104:S123-S124.

select

Fesnak, A., Mastoris, J., Ley, S., Henry, D.. Routine blood draw during chemotherapy does not cause significant iron deficiency. Blood. 2005; 106(11):8B.